

01702.4015LO

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
(Div. of U.S. Patent Appln. No. 09/674,973	:	
filed November 8, 2000))	Examiner: UNASSIGNED
	:	
GUSTAV GAUDERNACK, ET AL.)	
	:	Group Art Unit: UNASSIGNED
Application No.: UNASSIGNED)	
	:	
Filed: February 12, 2004)	
	:	
For: PEPTIDES)	February 12, 2004

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449.

These documents were previously cited during the prosecution of parent Application No. 09/674,674. Accordingly, no copies are being provided herewith, in accordance with 37 CFR 1.98(d).

FEE OR STATEMENT


No fee or statement is required in connection with this Information Disclosure Statement, since it is being submitted prior to (1) the issuance of a first official action on the merits and (2) expiration of the three-month period following filing of the above-captioned application.

REMARKS

It is respectfully requested that the cited information be considered by the Examiner and that an annotated copy of the enclosed Form PTO-1449 be returned with the next official communication, indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address given below.

Respectfully submitted,

A handwritten signature in black ink, reading "John W. Behringer". The signature is written in a cursive style with a horizontal line underneath the name.

John W. Behringer
Registration No. 23,086
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200
JWB/HC

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 12, 2004				ATTY DOCKET NO. 1702.4015LO		APPLICATION NO. Div. of 09/674,973	
				APPLICANT GUSTAV GAUDERNACK, ET AL.			
				FILING DATE February 12, 2004		GROUP Unassign d	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
		WO 99/10382	3/1999	WIPO			Yes
		WO 97/12992	4/1997	WIPO			Y s
		WO 96/18409	6/1996	WIPO			Yes
		WO 95/32731	12/1995	WIPO			Y s
		WO 92/14756	9/1992	WIPO			Y s

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Rampino et al. (1997), Science 275:967-969, "Somatic Frameshift Mutations in the BAX Gen in Colon Cancers of the Microsatellite Mutator Pheotype".
	Yamamoto et al. (1998, March), Cancer Research 58:997-1003, "Somatic Frameshift Mutations in DNA Mismatch Repair and Proapoptosis Genes in Hereditary Nonpolyposis Colorectal Cancer".
	Markowitz et al. (1995), Science 268:1336-1338, "Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability".
	Gaudernack (1996), Immunotechnology 2:3-9, "T cell responses against mutant ras: a basis for novel cancer vaccines".
	Gjertsen et al. (1996), Int. Journal of Cancer 65:450-453, "Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study".
	Gjertsen et al. (1996), British Journal of Cancer 74:1828-1833, "Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination".

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 12, 2004				ATTY DOCKET NO. 1702.4015LO		APPLICATION NO. Div. of 09/674,973	
				APPLICANT GUSTAV GAUDERNACK, ET AL.			
				FILING DATE Fbruary 12, 2004		GROUP Unassign d	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
		WO 99/58564	11/1999	WIPO			Yes
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Gjertsen et al. (1997), Int. J. Cancer 72:784-790, "Cytotoxic CD4⁺ and CD8⁺ T-Lymphocytes, Generated by Mutant p21-ras (12Val) Peptide Vaccination of a Patient, Recognize ... Tumour Cells Carrying This Mutation".					
		Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer".					
		Barinaga, (1992) Science, vol. 257, pp. 880-881, "Getting Some 'Backbone': How MHC Binds Peptides".					
		Deres et al., (1989) Nature, vol. 342, pp. 561-564, "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine".					
		Tighe et al., (1998) Immun. Today, vol. 19(2), pp. 89-97, "Gene vaccination: plasmid DNA is more than just a blueprint".					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2